Diagnostic value of neutrophil gelatinase-associated lipocalin, cystatin C, and soluble triggering receptor expressed on myeloid cells-1 in critically ill patients with sepsis-associated acute kidney injury

Critical Care

Volumn 19, Issue 1, 2015, Pages

  Dai, Xingui ^a,b   Zeng, Zhenhua ^a   Fu, Chunlai ^b   Zhang, Sheng'an ^b   Cai, Yeping ^b   Chen, Zhongqing ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b THE FIRST PEOPLE S HOSPITAL OF CHENZHOU   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN C; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; CST3 PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; LCN2 PROTEIN, HUMAN; LIPOCALIN; MEMBRANE PROTEIN; ONCOPROTEIN; TREM1 PROTEIN, HUMAN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BLOOD ANALYSIS; CRITICALLY ILL PATIENT; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RISK ASSESSMENT; SEPSIS; SURVIVAL RATE; URINALYSIS; ACUTE KIDNEY INJURY; AGED; BLOOD; CRITICAL ILLNESS; GENE EXPRESSION REGULATION; MIDDLE AGED; PROSPECTIVE STUDY; URINE;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; ADULT; AGED; BIOMARKERS; CRITICAL ILLNESS; CYSTATIN C; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIPOCALIN-2; LIPOCALINS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RECEPTORS, IMMUNOLOGIC; SEPSIS;

EID: 84930623610     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-015-0941-6     Document Type: Article

References (40)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-10.
2. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med. 2007;35:1244-50.
3. Hoste EA, Lameire NH, Vanholder RC, Benoit DD, Decruyenaere JM, Colardyn FA. Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol. 2003;14:1022-30.
4. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294:813-8.
5. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204-12.
6. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31.
7. Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. KDIGO Clinical Practice Guideline for Acute Kidney Injury 2012. Kidney Int Suppl. 2012;2:1-138.
8. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985;28:830-8.
9. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473-83.
10. Doi K, Yuen PS, Eisner C, Hu X, Leelahavanichkul A, Schnermann J, et al. Reduced production of creatinine limits its use as marker of kidney injury in sepsis. J Am Soc Nephrol. 2009;20:1217-21.
11. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365:1231-8.
12. Nejat M, Pickering JW, Walker RJ, Endre ZH. Rapid detection of acute kidney injury by plasma cystatin C in the intensive care unit. Nephrol Dial Transplant. 2010;25:3283-9.
13. Martensson J, Bell M, Oldner A, Xu S, Venge P, Martling CR. Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury. Intensive Care Med. 2010;36:1333-40.
14. Nejat M, Pickering JW, Walker RJ, Westhuyzen J, Shaw GM, Frampton CM, et al. Urinary cystatin C is diagnostic of acute kidney injury and sepsis, and predicts mortality in the intensive care unit. Crit Care. 2010;14:R85.
15. Royakkers AA, Korevaar JC, van Suijlen JD, Hofstra LS, Kuiper MA, Spronk PE, et al. Serum and urine cystatin C are poor biomarkers for acute kidney injury and renal replacement therapy. Intensive Care Med. 2011;37:493-501.
16. Su LX, Feng L, Zhang J, Xiao YJ, Jia YH, Yan P, et al. Diagnostic value of urine sTREM-1 for sepsis and relevant acute kidney injuries: a prospective study. Crit Care. 2011;15:R250.
17. de Geus HR, Betjes MG, Schaick R, Groeneveld JA. Plasma NGAL similarly predicts acute kidney injury in sepsis and nonsepsis. Biomark Med. 2013;7:415-21.
18. Matsa R, Ashley E, Sharma V, Walden AP, Keating L. Plasma and urine neutrophil gelatinase-associated lipocalin in the diagnosis of new onset acute kidney injury in critically ill patients. Crit Care. 2014;18:R137.
19. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14:2534-43.
20. Mussap M, Dalla VM, Fioretto P, Saller A, Varagnolo M, Nosadini R, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int. 2002;61:1453-61.
21. Aydogdu M, Gursel G, Sancak B, Yeni S, Sari G, Tasyurek S, et al. The use of plasma and urine neutrophil gelatinase associated lipocalin (NGAL) and Cystatin C in early diagnosis of septic acute kidney injury in critically ill patients. Dis Markers. 2013;34:237-46.
22. Li Y, Li X, Zhou X, Yan J, Zhu X, Pan J, et al. Impact of sepsis on the urinary level of interleukin-18 and cystatin C in critically ill neonates. Pediatr Nephrol. 2013;28:135-44.
23. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol. 2000;164:4991-5.
24. Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature. 2001;410:1103-7.
25. Gibot S, Massin F. Soluble form of the triggering receptor expressed on myeloid cells 1: an anti-inflammatory mediator? Intensive Care Med. 2006;32:185-7.
26. Gibot S. Clinical review: role of triggering receptor expressed on myeloid cells-1 during sepsis. Crit Care. 2005;9:485-9.
27. Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol. 2006;7:1266-73.
28. Zhang J, She D, Feng D, Jia Y, Xie L. Dynamic changes of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) reflect sepsis severity and can predict prognosis: a prospective study. BMC Infect Dis. 2011;11:53.
29. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1-201.
30. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31:1250-6.
31. Katagiri D, Doi K, Matsubara T, Negishi K, Hamasaki Y, Nakamura K, et al. New biomarker panel of plasma neutrophil gelatinase-associated lipocalin and endotoxin activity assay for detecting sepsis in acute kidney injury. J Crit Care. 2013;28:564-70.
32. Martensson J, Martling CR, Oldner A, Bell M. Impact of sepsis on levels of plasma cystatin C in AKI and non-AKI patients. Nephrol Dial Transplant. 2012;27:576-81.
33. Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17:R25.
34. Liebetrau C, Gaede L, Doerr O, Blumenstein J, Rixe J, Teichert O, et al. Neutrophil gelatinase-associated lipocalin (NGAL) for the early detection of contrast-induced nephropathy after percutaneous coronary intervention. Scand J Clin Lab Invest. 2014;74:81-8.
35. Determann RM, Schultz MJ, Geerlings SE. Soluble triggering receptor expressed on myeloid cells-1 is not a sufficient biological marker for infection of the urinary tract. J Infect. 2007;54:e249-50.
36. Kiers HD, de Sevaux R, Pickkers P. Cystatin C is not a reliable marker of residual glomerular filtration rate during continuous renal replacement therapy. Intensive Care Med. 2011;37:1893-4. Author reply 1897-8.
37. Mayeur N, Rostaing L, Nogier MB, Jaafar A, Cointault O, Kamar N, et al. Kinetics of plasmatic cytokines and cystatin C during and after hemodialysis in septic shock-related acute renal failure. Crit Care. 2010;14:R115.
38. Candido S, Maestro R, Polesel J, Catania A, Maira F, Signorelli SS, et al. Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget. 2014;5:1576-94.
39. Karapanagiotou EM, Pelekanou E, Charpidou A, Tsaganos T, Anagnostou V, Plachouras D, et al. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies. Anticancer Res. 2008;28:1411-5.
40. Wang F, Pan W, Wang H, Zhou Y, Wang S, Pan S. The impacts of thyroid function on the diagnostic accuracy of cystatin C to detect acute kidney injury in ICU patients: a prospective, observational study. Crit Care. 2014;18:R9.